Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.53 |
| ▸ | MDM4 | O15151 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29929404 | 0.88 | MDM4 (0.51) | MDM2MDM4TP53SLC17A5CASP3 | |
| SCHEMBL29899340 | 0.88 | MDM4 (0.51) | MDM2MDM4TP53SLC17A5CASP3 | |
| SCHEMBL12491518 | 0.88 | MDM4 (0.51) | MDM2MDM4TP53SLC17A5CASP3 | |
| SCHEMBL799728 | 0.88 | MDM4 (0.51) | MDM2MDM4TP53SLC17A5CASP3 | |
| SCHEMBL22636173 | 0.86 | MDM2 (0.60) | MDM2MDM4TP53PIN1SLC17A5 | |
| SCHEMBL29855146 | 0.86 | MDM2 (0.60) | MDM2MDM4TP53PIN1SLC17A5 | |
| SCHEMBL29634850 | 0.86 | MDM2 (0.60) | MDM2MDM4TP53PIN1SLC17A5 | |
| SCHEMBL22636171 | 0.86 | MDM2 (0.60) | MDM2MDM4TP53PIN1SLC17A5 | |
| SCHEMBL30819642 | 0.85 | MDM2 (0.56) | MDM2MDM4TP53PIN1SLC17A5 | |
| SCHEMBL27393601 | 0.85 | MDM2 (0.56) | MDM2MDM4TP53PIN1SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011639-B2 | Peptidomimetic compounds | NOLIVA THERAPEUTICS LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170037085-A1 | PEPTIDOMIMETIC COMPOUNDS | NOLIVA THERAPEUTICS LLC (US) | 2017-02-09 | — | — | US | disclosed |
| US-9493510-B2 | Peptidomimetic compounds | NOLIVA THERAPEUTICS LLC (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150353606-A1 | PEPTIDOMIMETIC COMPOUNDS | NOLIVA THERAPEUTICS LLC (US) | 2015-12-10 | — | — | US | disclosed |
| WO-2014110420-A1 | PEPTIDOMIMETIC COMPOUNDS | NOLIVA THERAPEUTICS LLC (US) | 2014-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011639-B2 | Peptidomimetic compounds | BCL2A1, MCL1, BCL2L1 | MDM2 76/4885MDM4 1562/4885TP53 51/4885 |
| US-20150353606-A1 | PEPTIDOMIMETIC COMPOUNDS | BCL2A1, MCL1, BCL2L1 | MDM2 76/4885MDM4 1562/4885TP53 51/4885 |
| US-20170037085-A1 | PEPTIDOMIMETIC COMPOUNDS | BCL2A1, MCL1, BCL2L1 | MDM2 76/4885MDM4 1562/4885TP53 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.